Accueil
Explorer
nav.journalClub
Tendances
Plus
Synapse
⌘+K
Synapse
Langue
Français
Français
Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer | Synapse
September 16, 2025
View Full Paper
Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
RY
Rona Yaeger
Memorial Sloan Kettering Cancer Center
JM
Jean-François Martini
Pfizer (United States)
LP
Lincoln W. Pasquina
Boston Foundation
See all
Key Points
Analysis indicates significant differences in tumor fraction in F1LCDx−/CTA+ and F1LCDx+/CTA− subsets.
Findings reveal the potential impact of foundationone liquid cdx for detecting braf v600e in colorectal cancer.
Study highlights the importance of precise tumor fraction assessment in colorectal cancer diagnostics.
Data demonstrates how rising tumor fractions could improve the detection accuracy for braf v600e alterations.
Abstract
Tumor fraction in F1LCDx−/CTA+ and F1LCDx+/CTA− subsets.
Demander à l'IA
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Demander à l'IA
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Yaeger et al. (Tue,) studied this question.
synapsesocial.com/papers/68d4565b31b076d99fa5b21f
https://doi.org/https://doi.org/10.1158/2767-9764.30083880